ISLB 2021 | Will liquid biopsies replace traditional risk factors in RCC?

Toni Choueiri, MD, Dana Farber Cancer Institute, Boston, MA, discusses whether liquid biopsy could replace traditional risk factors in renal cell carcinoma (RCC). A big challenge for the diagnosis of RCC is detecting the low level of ctDNA, for which liquid biopsy is a promising possible solution. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.